Poland's largest medical diagnostics laboratory chain, providing lab testing and diagnostic imaging services nationwide.
Poland's largest medical diagnostics laboratory chain, providing lab testing and diagnostic imaging services nationwide.
Paid either by the national health fund under contracts with set volumes, or directly by private patients and employers; lab tests are the bulk of the work, with imaging and genetics on top. It has grown mostly by buying smaller laboratories in a fragmented Polish market.
In one line: Poland's largest medical diagnostics lab chain, like a Polish Quest Diagnostics.
Moat: narrow (scale, distribution, brand). Largest diagnostic lab network in Poland with scale and NFZ contract relationships.
Headquarters: Krakow, Poland · Founded: 2001 · Employees: 7,635
Size Diagnostyka (DIA.WA) is a Poland Health Care company (Medical/Nursing Services) with a market value of $1.28B, the 35th largest of 82 Poland companies the cockpit tracks. Shares closed at PLN 152.00 on 18 Nov 2026.
Performance Over six months the shares fell 5.7%, against +17.1% for the median peer and +14.0% for the Poland market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 19.2% over the last twelve months (peer median +7.9%); the operating margin is 14.5% (peer median 3.5%).
Valuation It trades at 19.5× forward earnings against a peer median of 29.4× (6th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.9 points above its cost of capital (9.5% WACC).
Next results Next results expected around 26 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | PLN 2.58B | PLN 2.41B | PLN 1.95B | PLN 1.59B | PLN 1.44B |
| Revenue growth | — | +24% | +23% | +11% | — |
| Gross profit | PLN 433M | PLN 429M | PLN 355M | PLN 265M | PLN 278M |
| EBITDA | PLN 596M | PLN 581M | PLN 481M | PLN 378M | PLN 362M |
| Net income | PLN 255M | PLN 252M | PLN 223M | PLN 123M | PLN 167M |
| Free cash flow | PLN 251M | PLN 281M | PLN 229M | PLN 214M | PLN 177M |
| Capital expenditure | PLN 202M | PLN 205M | PLN 133M | PLN 81.3M | PLN 89.4M |
| Total debt | PLN 1.22B | PLN 1.08B | PLN 969M | PLN 850M | PLN 721M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Diagnostyka DIA.WA | $1.28B | -6% | +19% | 15% | 19.5× | 7.3% |
| Medicover MCOV-B.ST | $3.87B | +21% | +3% | 7% | 36.1× | 19.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DIA.WA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.9% | +1.3% | 9th lowest of 21 |
| 6-month return | -5.7% | +17.1% | 6th lowest of 21 |
| Distance from 52-week high | -26.9% | -22.2% | 9th lowest of 21 |
| Revenue growth (TTM) | +19.2% | +7.9% | 5th highest of 21 |
| Operating margin | 14.5% | 3.5% | 4th highest of 21 |
| Forward P/E | 19.5× | 29.4× | 6th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 7.3% | 11.5% | 7th least demanding of 15 |
| Growth delivered (Del g) | +18.9% | +11.8% | 4th highest of 15 |
| Hurdle (Req g minus delivered) | -11.6 pp | +0.8 pp | 3rd least demanding of 15 |
| ROIC minus cost of capital | +7.9 pp | -3.8 pp | 3rd highest of 19 |
| EV / EBITDA | 10.7× | 10.7× | 8th cheapest of 15 |
| Net debt / EBITDA | 2.0× | 1.3× | 8th most indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Diagnostyka DIA.WA | Poland | $1.28B | -6% | +19% | 15% | 19.5× | 7.3% | +18.9% |
| Pennant PNTG | United States | $1.26B | +1% | +39% | 6% | 23.7× | 20.7% | +19.4% |
| OPKO Health OPK | United States | $1.25B | +37% | -22% | -29% | n/a | n/a | n/a |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +11% | +20% | 18% | 44.5× | 32.4% | +10.5% |
| Clariane CLARI.PA | France | $1.32B | -20% | +1% | 6% | 8.2× | 6.8% | +6.5% |
| Lumexa Imaging LMRI | United States | $1.35B | +89% | +8% | 2% | 16.0× | n/a | n/a |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 33.5× | 3.5% | -5.1% |
| Nutex Health NUTX | United States | $1.19B | +42% | -19% | 39% | 6.5× | -18.0% | +253.5% |
| GoodRx GDRX | United States | $1.15B | +33% | -2% | 12% | 10.6× | 6.3% | +7.7% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 29.4× | 18.8% | +13.0% |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 39.9× | 9.7% | +2.1% |
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | n/a | -6.4% | +18.3% |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 34.1× | n/a | n/a |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 54.2× | n/a | n/a |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 15.2× | 1.1% | +7.7% |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | n/a | n/a | n/a |
| Novogene 688315.SS | China | $1.01B | +13% | +6% | 7% | 44.8× | 13.9% | +8.2% |
| AdaptHealth AHCO | United States | $1.01B | -30% | -3% | 3% | n/a | 16.8% | +25.2% |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | n/a | n/a | n/a |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.69B | +18% | +24% | 32% | 63.0× | 40.4% | +16.7% |
| Regis Healthcare REG.AX | Australia | $962M | -28% | +17% | 4% | 25.3× | 13.3% | +14.4% |